These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

383 related items for PubMed ID: 27696232

  • 1. Correlation of BRAF mutation and SUVmax levels in thyroid cancer patients incidentally detected in 18F-fluorodeoxyglucose positron emission tomography.
    Ozderya A, Temizkan S, Gul AE, Ozugur S, Sargin M, Aydin K.
    Endocrine; 2017 Jan; 55(1):215-222. PubMed ID: 27696232
    [Abstract] [Full Text] [Related]

  • 2. Relationship Between 18F-fluorodeoxyglucose Accumulation and the BRAF V600E Mutation in Papillary Thyroid Cancer.
    Chang JW, Park KW, Heo JH, Jung SN, Liu L, Kim SM, Kwon IS, Koo BS.
    World J Surg; 2018 Jan; 42(1):114-122. PubMed ID: 28808756
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Correlation of BRAFV600E Mutation and Glucose Metabolism in Thyroid Cancer Patients: An ¹⁸F-FDG PET Study.
    Nagarajah J, Ho AL, Tuttle RM, Weber WA, Grewal RK.
    J Nucl Med; 2015 May; 56(5):662-7. PubMed ID: 25814520
    [Abstract] [Full Text] [Related]

  • 7. Clinicopathological characteristics including BRAF V600E mutation status and PET/CT findings in papillary thyroid carcinoma.
    Choi EK, Chong A, Ha JM, Jung CK, O JH, Kim SH.
    Clin Endocrinol (Oxf); 2017 Jul; 87(1):73-79. PubMed ID: 28329426
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. mRNA Expression of SLC5A5 and SLC2A Family Genes in Papillary Thyroid Cancer: An Analysis of The Cancer Genome Atlas.
    Suh S, Kim YH, Goh TS, Jeong DC, Lee CS, Jang JY, Cha W, Han ME, Kim SJ, Kim IJ, Pak K.
    Yonsei Med J; 2018 Aug; 59(6):746-753. PubMed ID: 29978611
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Non-FDG-avid primary papillary thyroid carcinoma may not differ from FDG-avid papillary thyroid carcinoma.
    Kim MH, Ko SH, Bae JS, Lee SH, Jung CK, Lim DJ, Baek KH, Kim SH, Lee JM, Kang MI, Cha BY.
    Thyroid; 2013 Nov; 23(11):1452-60. PubMed ID: 23688271
    [Abstract] [Full Text] [Related]

  • 12. The significance and management of incidental [18F]fluorodeoxyglucose-positron-emission tomography uptake in the thyroid gland in patients with cancer.
    Eloy JA, Brett EM, Fatterpekar GM, Kostakoglu L, Som PM, Desai SC, Genden EM.
    AJNR Am J Neuroradiol; 2009 Aug; 30(7):1431-4. PubMed ID: 19342543
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. 18F-FDG-Avid Thyroid Incidentalomas: The Importance of Contextual Interpretation.
    Pattison DA, Bozin M, Gorelik A, Hofman MS, Hicks RJ, Skandarajah A.
    J Nucl Med; 2018 May; 59(5):749-755. PubMed ID: 29025986
    [Abstract] [Full Text] [Related]

  • 16. Clinical significance of focal and diffuse thyroid diseases identified by (18)F-fluorodeoxyglucose positron emission tomography.
    Salvatori M, Melis L, Castaldi P, Maussier ML, Rufini V, Perotti G, Rubello D.
    Biomed Pharmacother; 2007 Sep; 61(8):488-93. PubMed ID: 17604940
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Diagnosis of incidental thyroid nodules on 18F-fluorodeoxyglucose positron emission tomography imaging: are these significant?
    Sharma SD, Jacques T, Smith S, Watters G.
    J Laryngol Otol; 2015 Jan; 129(1):53-6. PubMed ID: 25496842
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.